Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

that lay people, and organisations representing their interests, have opportunities to contribute to developing NICE guidance, advice and quality standards, and support their implementation, and that, ...

Abuse and neglect can have a long-lasting impact on the health and wellbeing of children and young people. It is important to know how to respond, and the evidence suggests that the following ...

Suggested remit: To appraise the clinical and cost effectiveness of Vosoritide within its marketing authorisation for treating achondroplasia in children.

A list of downloadable documents created during development.